EGFR and lung cancer: Non‐small cell lung cancer (NSCLC) is a major type (~85%) of lung cancer, and its targeted therapy is tried such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs); however, the treatment still limited due to acquired resistance and deficient efficacy.3